Efficacy of tulathromycin compared with tilmicosin and florfenicol for the control of respiratory disease in cattle at high risk of developing bovine respiratory disease.
Three studies conducted at feedlots in Colorado, Idaho, and Texas examined the comparative efficacy of tulathromycin injectable solution for the treatment of cattle at high risk of developing undifferentiated bovine respiratory disease (BRD). Each study randomly allocated 250 calves to receive tulathromycin at 2.5 mg/kg and 250 calves to receive either tilmicosin at 10 mg/kg (Colorado site) or florfenicol at 40 mg/kg (Idaho and Texas sites) on arrival at the feedlot. Calves were housed by treatment group in pens with 50 calves/pen. Beginning 3 days after antimicrobial treatment, cattle were observed for signs of BRD daily until harvest. In all three studies, the treatment success rates at 28 days after treatment and at harvest were significantly higher (P < or = .013) for cattle treated with tulathromycin than for cattle treated with either tilmicosin or florfenicol. Fewer tulathromycin-treated cattle were removed from the group as "chronics" or "mortalities" at 28 days posttreatment (P < or = .014) in all three studies. Tulathromycin demonstrated superior efficacy compared with tilmicosin and florfenicol when treating groups of high-risk cattle before the onset of signs of BRD.
Rooney
Kathleen A
KA
Pfizer Animal Health, Veterinary Medicine Research and Development, Kalamazoo, MI 49001, USA.
Nutsch
Robert G
RG
Skogerboe
Terry L
TL
Weigel
Daniel J
DJ
Gajewski
Kimberly
K
Kilgore
W Randal
WR
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002417:Cattle; D004187:Disaccharides / Q000008:administration & dosage / Q000627:therapeutic use*; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D007279:Injections, Subcutaneous / Q000662:veterinary; D018942:Macrolides / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D012766:Pasteurellosis, Pneumonic / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D012008:Recurrence; D012307:Risk Factors; D012720:Severity of Illness Index; D013839:Thiamphenicol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome; D015645:Tylosin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D014481:United States
D000900:Anti-Bacterial Agents; D004187:Disaccharides; D006571:Heterocyclic Compounds; D018942:Macrolides; C035534:florfenicol; D013839:Thiamphenicol; C485204:tulathromycin; C052319:tilmicosin; D015645:Tylosin